Please Wait
Applying Filters...
Menu
$ API Ref.Price (USD/KG) : 219Xls

Digital Content read-more

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218899

FDA
20 Nov 2024

https://www.globenewswire.com/news-release/2024/11/11/2978267/18362/en/Investigators-to-Present-New-REDUCE-IT-Subanalysis-of-VASCEPA-VAZKEPA-icosapent-ethyl-in-Patients-With-and-Without-Coronary-Artery-Disease-History-and-Mechanistic-Data-on-Eicosapen.html

GLOBENEWSWIRE
11 Nov 2024

https://www.globenewswire.com/news-release/2024/09/09/2942721/18362/en/Research-Highlighting-the-Clinical-Impact-of-VASCEPA-VAZKEPA-icosapent-ethyl-in-Patients-with-Diabetes-and-High-Cardiovascular-Risk-and-the-Anti-Lp-a-Oxidation-Mechanistic-Effect-o.html

GLOBENEWSWIRE
09 Sep 2024

https://www.globenewswire.com/news-release/2024/07/17/2914903/18362/en/Amarin-Receives-National-Reimbursement-for-VAZKEPA-icosapent-ethyl-in-Portugal.html

GLOBENEWSWIRE
17 Jul 2024

https://www.globenewswire.com/news-release/2024/07/08/2909539/18362/en/Amarin-Partner-EddingPharm-Receives-Regulatory-Approval-for-VASCEPA-Icosapent-Ethyl-in-Mainland-China-for-Cardiovascular-Risk-Reduction-CVRR.html

GLOBENEWSWIRE
08 Jul 2024

https://www.reuters.com/legal/litigation/drugmaker-apotex-accuses-amarin-vascepa-monopoly-us-lawsuit-2024-06-17/

REUTERS
18 Jun 2024